COVID-19 Vaccine Effectiveness Studies Show Waning Protection Over Time, Supporting Annual Vaccination
核心洞察
Two major studies demonstrate that COVID-19 (搜索) vaccines provide meaningful protection against severe outcomes, with effectiveness ranging from 24-64% depending on the endpoint measured.
Vaccine effectiveness significantly decreases over time, dropping from approximately 50% in the first two months to negative or minimal protection after six months post-vaccination.
The 2024-2025 COVID vaccine (搜索) showed 29% effectiveness against emergency department visits, 39% against hospitalizations, and 64% against deaths among U.S. veterans over six months of follow-up.
Two comprehensive studies published in major medical journals provide new evidence on COVID-19 vaccine effectiveness, revealing both the continued benefits and limitations of current vaccination strategies. The research demonstrates that while vaccines offer meaningful protection against severe outcomes, their effectiveness wanes significantly over time, supporting the need for annual vaccination updates.
Vaccine Effectiveness Against Emergency Care and Hospitalizations
A study published in JAMA Network Open analyzed data from 345,639 emergency department and urgent care visits across 6 healthcare systems in 8 states. The research found that 2023-2024 COVID-19 (搜索) vaccines provided 24% effectiveness against COVID-19-associated encounters during the 7 to 299 days post-vaccination period.
The effectiveness varied dramatically by time since vaccination. During the first 7 to 59 days post-vaccination, vaccine effectiveness reached 49%, but declined sharply to −7% at 180 to 299 days post-vaccination. For hospitalizations, the pattern was similar, with overall effectiveness of 29% during the 7 to 299 days period, starting at 51% effectiveness in the first two months and dropping to −4% after six months.
"Persons who did not receive 2023-2024 COVID-19 (搜索) vaccines were more susceptible to SARS-CoV-2 (搜索) infection soon after 2023-2024 COVID-19 vaccine (搜索) rollout," the study authors noted.
Veterans Study Confirms Protection Against Severe Outcomes
A separate study published in The New England Journal of Medicine examined 295,971 VA (搜索) patients, including 164,132 veterans who received the 2024-2025 COVID vaccine (搜索) and 131,839 who did not. This research found higher effectiveness rates against the most severe outcomes, with vaccine effectiveness estimated at 29% for emergency department visits, 39% for hospitalizations, and 64% for deaths over six months of follow-up.
The combined effectiveness against all three outcomes was 28%, though protection decreased over time, falling to approximately 21% after four to six months. The study found benefits across all age groups and among those with chronic health conditions.
Age and Risk Factor Considerations
Both studies revealed important patterns related to age and underlying health conditions. In the JAMA study, vaccine effectiveness for hospitalizations among patients 65 years and older was 54% during the 7 to 59 days post-vaccination period, compared with 31% for those aged 18 to 64 years.
Immunocompromised patients showed distinct patterns in vaccination behavior and outcomes. These patients were more likely to receive COVID-19 (搜索) vaccines during the 2023-2024 season (27%) compared with non-immunocompromised patients (22%). Additionally, immunocompromised patients were more likely to be admitted to intensive care units (21%) compared with non-immunocompromised patients (14%).
Variant-Specific Performance
The research captured vaccine performance during different variant predominance periods. In the JAMA study, 69% of encounters occurred during JN.1 predominance, with vaccines showing lower protection during this period compared to earlier variants. The study authors emphasized "the likely importance of receiving updated COVID-19 (搜索) vaccination" given the reduced effectiveness against newer variants.
Public Health Impact and Uptake Challenges
Despite demonstrated effectiveness, vaccine uptake remains a challenge. The Veterans Affairs study noted that adult uptake of the 2024-2025 vaccine stalled at around 21% by late December 2024—half the uptake of the influenza vaccine during the same period and the lowest since COVID vaccines became available.
The research highlighted the continued role of pharmacists in vaccination efforts, noting that pharmacy teams conducted more than 42 million COVID-19 (搜索) tests and over 270 million vaccinations from February 2020 through September 2022, accounting for approximately 50% of all COVID-19 vaccines administered in the United States.
Clinical Implications
Both studies concluded that COVID-19 (搜索) vaccines continue to provide meaningful protection despite waning effectiveness. The JAMA study authors stated: "The 2023-2024 COVID-19 vaccines were associated with additional protection against COVID-19–associated ED and UC encounters, hospitalization, and critical illness beyond existing protection provided by prior vaccination or SARS-CoV-2 (搜索) infection."
The research supports current recommendations for annual COVID-19 (搜索) vaccination, particularly for high-risk populations including older adults and immunocompromised individuals. However, the studies also highlight the need for strategies to extend vaccine protection duration and improve uptake rates across all population groups.